



ASX Media Release

2 November 2006

First International Export Order for Travelan **Australian developed therapeutic product begins global expansion**

Australian biopharmaceutical company Anadis Limited (ASX:ANX) is pleased to announce the Canadian distributor, Valeo Pharma, have placed their initial order for Travelan - used to reduce the risk of Travellers' Diarrhoea. This is a significant order for 10,000 packets, representing the first wholesale order for Travelan to an established overseas distributor of healthcare products. Canada is seen as a crucial market in expanding Travelan into North America.

Valeo Pharma is investing significant resources in the areas of marketing and product promotions in order to establish Travelan with in Canada. The distribution agreement sees Valeo Pharma as the Canadian distributor for at least the next 5 years, commencing with this initial order.


Anadis anticipates the international distribution of Travelan to grow, with the expectation of the appointment of a US distributor in the short term, and subsequent order, as well as entry into additional international markets.

The Canadian Market

The product launch will coincide with the "Snow Bird" travel season, as many Canadians travel to warmer climates to escape the winter. Popular destinations include the high travellers' diarrhoea risk destinations of Mexico, The Caribbean and Latin America.

The Canadian market is seen as a stepping stone to the US market, but is important nevertheless being approximately 30% larger than Australia (with a population of approximately 30 million).

New Packaging



Travelan is to be sold in the new and improved packaging, redesigned to incorporate generally recognised colours and packaging, which underline vacation and relaxation, and those predominately associated internationally for gastrointestinal type healthcare products

Valeo Pharma Inc.

Anadis has chosen Valeo Pharma Inc. as the distributor for Travelan in the Canadian market due to its success in acquiring and marketing OTC (Over The Counter) and prescription products in Canada. Valeo Pharma has a proven track record in the management of distribution and commercialisation responsibilities for third party products.

Valeo Pharma has the experience and ability to successfully and aggressively promote products through targeted innovative marketing and sales activities, with their strategies focusing on strengthening trade commitment and increasing brand awareness among physicians, pharmacists and other healthcare professionals.

About Valeo Pharma



VALEO PHARMA
products.

Valeo Pharma Inc. is a Canadian specialty pharmaceutical company which acquires branded pharmaceutical products from partners. Valeo Pharma strives to provide niche patient populations and consumers with quality OTC and prescription

Valeo Pharma usually acquires mature brands that continue to provide sought-after therapeutic benefits as well as innovative or promising late-stage development products. Visit www.valeopharma.com for more information.

Travelan – Natural and Effective

Travelan, a natural, clinically proven therapy is a revolutionary over-the-counter (OTC) preparation scientifically and clinically proven to significantly reduce the risk of getting the medical condition known as travellers' diarrhoea.

Travelan is prepared from naturally derived antibodies against 13 strains of *E. coli* that are the most common cause of travellers' diarrhoea. Travelan is high in antibodies that bind to certain intestinal bacteria and bacterial by-products, and is not an antibiotic preparation - therefore not associated with the usual negative antibiotic side effects.

Travelan is a natural product that will enable travel with reduced fear of becoming ill due to exposure to *E.coli* bacteria. In hospital clinical trials in the US and Europe, Travelan has shown up to 90% protection against Enterotoxigenic *E. coli* (ETEC), the main cause of Travellers' Diarrhoea.



Potential Additional Gastrointestinal Indications for Travelan

Anadis will be investigating the use of Travelan for additional gastrointestinal therapeutic indications as a result of positive clinical feedback from a number of healthcare providers including medical specialists.

Reports to the company indicate that a number of patients with a range of gastrointestinal conditions, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and ulcerative colitis, have experienced an improvement in some their symptoms (e.g. diarrhoea) whilst taking Travelan to reduce their risk of travellers' diarrhoea.

Travellers Diarrhoea

Travellers' diarrhoea (otherwise known as Delhi Belly, Montezuma's Revenge, Tourist Trots and The Flux etc) is described as the number one health problem for international travellers, in terms of frequency and economic impact. Travellers' diarrhoea is normally accompanied by other clinical features such as nausea, bloating, abdominal cramps and fever. Travelan significantly reduces the risk of being affected in the first instance.

For more information please visit www.travelan.com.au

Visit our websites: www.anadis.com.au and www.travelan.com.au

Anadis – Delivering On The Promise Of Biotechnology



About Anadis Limited:

Anadis, a Melbourne based biopharmaceutical company is focused on Nutraceutical and Pharmaceutical research and development. Anadis is a specialist in the development of bovine colostrum derived products for therapeutic use in humans. Projects include:

Anadis' first commercialised product: **Travelan** is a natural product, which significantly decrease the risk of the medical condition known as Travellers Diarrhoea and the symptoms of gastrointestinal disorders. Travelan is a colostrum preparation, against the common strains of *E.coli* – the most common cause of Travellers.

Travelan has received a "Green Light" for sales in the US and a distributor in Canada has been appointed. Travelan is being considered for other markets including: Singapore, India, Korea, United Arab Emirates, Thailand, Malaysia, South Africa and the UK and EU.

Travelan has recently been potentially identified for additional gastrointestinal indications including Irritable Bowel Syndrome IBS and Inflammatory Bowel Disorder IBD.

For more information please visit www.travelan.com.au

EV-71 - a bioactive protein based preventative product against Enterovirus 71, a debilitating polio like disease, is one of the viruses that causes 'hand, foot and mouth' or 'slapped cheek' disease. A significant proportion of younger children effected can develop nervous signs such as fits, paralysis and Enterovirus 71 has the potentially to be fatal. Anadis is now preparing colostrum antibodies for commercialisation in an anti-EV71 preventative, set to begin marketing in Taiwan during the northern hemisphere summer of 2007.

A set of **Bio-Defence** and **Respiratory Protection** technologies, a project in conjunction with the Australian Department of Defence and US Bio-Defence Organisations, initially focused on short-term immediate protection from airborne bacteria such as Anthrax and Plague, future civilian applications include Hay Fever and Asthma.

This project is expanding to examine the use of antibodies in providing respiratory protection against **Influenza** virus.

Bio-Shield 10 a range of "bio-shielding" technologies which protect delicate molecules, enzymes and proteins, initially targeted for use in the pro-biotic market.

Development into an **Immune Stimulating Infant Formula** is underway, initially destined for the Asian market.

Pyloran, which has been clinically proven to reduce levels of *H.pylori* bacteria in the stomach and reduce the symptoms of *H.pylori* associated gastritis - Anadis is also in early development of a ***H.pylori* vaccine**.

For further information, please contact:

Conor Graham - Chief Executive Officer

Email: conor.g@anadis.com.au

+61 3 9358 6388

Arie Nudel – Investor Relations

Email: arie.n@anadis.com.au

+61 3 9358 6388

